EUVIMEDEUVIMED entdecken
Crossref

Treatment and Long-Term Safety Outcomes of Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumours: An Asian Experience

Wei Ying Tham, Hian Liang Huang, David Wai Meng Tai, John C Allen, Jacqueline S G Hwang, Lih Ming Loh, Brian K P Goh, Simon Y K Ong, Peng Chin Kek, Damien M Y Tan, David C E Ng, Kelvin S H Loke

Neuroendocrinology · 2024

DOI: 10.1159/000538523 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuroendocrinology, 2024. Verfasst von Wei Ying Tham und 11 weiteren Autor:innen. Beteiligte Einrichtung: Singapore General Hospital, Department of Nuclear Medicine and Molecular Imaging, Singapore, Singapore. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Receptors, Peptide. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Peptide receptor radionuclide therapy (PRRT) is a targeted molecular therapy used to treat neuroendocrine tumours (NETs). It has been shown to be effective and well tolerated in patients with metastatic NETs in several centres in the USA, Europe, and Australia. Tolerability and efficacy data emerging from Asian centres remain few. Epidemiological evidence suggests that there are differences in neuroendocrine neoplasms between the population groups. We aim to describe the treatment and safety outcomes of PRRT in the Asian population.

Methods

One hundred and seven (107) patients with metastatic NETs who had undergone PRRT treatment from January 2012 to March 2019 were included in this retrospective study. The response rates using RECIST 1.1 and qualitative analysis were examined. The overall and progression-free survival curves were also evaluated.

Results

The median progression-free survival was 49 months. Response assessment after completion of treatment showed that 33 (37.9%) of 87 patients had partial or complete response. Subgroup analysis comparing high- and low-grade NET showed that there was a significant difference in the time to progression curves. Comparison of the number of cycles and progression-free and overall survival also showed a significant difference. Ten patients (9%) had grade 3 or more haematological toxicities. Four patients (4%) had grade 3/4 hepatobiliary toxicities, although the presence of extensive liver metastases was a confounding factor. None of the patients had grade 3/4 acute kidney injury.

Conclusion

Our results show that PRRT is safe and effective in the treatment of metastatic NET in the Asian population. There was a significant difference in the progression-free survival curves between low-grade and high-grade NET and in the progression-free and overall survival comparing the number of cycles received.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsReceptors, PeptideHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdultTreatment OutcomeOctreotideProgression-Free SurvivalAged, 80 and overAsian PeopleRadiopharmaceuticalsRadioisotopesNeoplasm Metastasis

Stichwörter der Autor:innen

Molecular therapyNeuroendocrine tumourPeptide receptor radionuclide therapy

Substanzen

Receptors, PeptideOctreotideRadiopharmaceuticalsRadioisotopes

Autor:innen und Institutionen

  • Singapore General Hospital, Department of Nuclear Medicine and Molecular Imaging, Singapore, Singapore.
  • Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
  • Duke-NUS Graduate Medical School, Singapore, Singapore.
  • Department of Pathology, Singapore General Hospital, Singapore, Singapore.
  • Department of Endocrinology, Singapore General Hospital, Singapore, Singapore.
  • Department of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital and National Cancer Centre Singapore, Singapore, Singapore.

Zitieren

APA

Tham, W. Y., Huang, H. L., Tai, D. W. M., Allen, J. C., Hwang, J. S. G., Loh, L. M., Goh, B. K. P., Ong, S. Y. K., Kek, P. C., Tan, D. M. Y., Ng, D. C. E., & Loke, K. S. H. (2024). Treatment and Long-Term Safety Outcomes of Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumours: An Asian Experience. Neuroendocrinology. https://doi.org/10.1159/000538523

Vancouver

Tham WY, Huang HL, Tai DWM, Allen JC, Hwang JSG, Loh LM, et al. Treatment and Long-Term Safety Outcomes of Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumours: An Asian Experience. Neuroendocrinology. 2024. doi:10.1159/000538523

BibTeX
@article{Tham2024,
  author = {Tham, Wei Ying and Huang, Hian Liang and Tai, David Wai Meng and Allen, John C and Hwang, Jacqueline S G and Loh, Lih Ming and Goh, Brian K P and Ong, Simon Y K and Kek, Peng Chin and Tan, Damien M Y and Ng, David C E and Loke, Kelvin S H},
  title = {Treatment and Long-Term Safety Outcomes of Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumours: An Asian Experience},
  journal = {Neuroendocrinology},
  year = {2024},
  doi = {10.1159/000538523}
}
Kostenlos starten →